Article
Cardiac & Cardiovascular Systems
Yohei Sotomi, Shungo Hikoso, Daisaku Nakatani, Hiroya Mizuno, Katsuki Okada, Tomoharu Dohi, Tetsuhisa Kitamura, Akihiro Sunaga, Hirota Kida, Bolrathanak Oeun, Taiki Sato, Sho Komukai, Shunsuke Tamaki, Masamichi Yano, Takaharu Hayashi, Akito Nakagawa, Yusuke Nakagawa, Yoshio Yasumura, Takahisa Yamada, Yasushi Sakata
Summary: In patients with HFpEF, female sex is independently associated with a higher prevalence of diastolic dysfunction and worse clinical outcomes compared to male sex. Despite differences in diastolic dysfunction, there was no significant difference in the incidence of clinical endpoints between women and men.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2021)
Article
Critical Care Medicine
Inderjit Singh, Rudolf K. F. Oliveira, Paul M. Heerdt, Rosa Pari, David M. Systrom, Aaron B. Waxman
Summary: Male patients with HFpEF showed more compromised dynamic RV-PA uncoupling and reduced peak VO2 compared to female patients. This was due to impaired RV contractility and afterload mismatch, while female patients with HFpEF maintained RV-PA coupling during exercise and had better peak exercise VO2 compared to male patients.
Article
Cardiac & Cardiovascular Systems
Deng Shuaishuai, Lin Jingyi, Zhao Zhiqiang, Fan Guanwei
Summary: This article reviews the parallel pathogenesis of HFpEF and introduces sex differences and the potential effect of estrogen in this condition.
HEART FAILURE REVIEWS
(2023)
Article
Cardiac & Cardiovascular Systems
Barry A. Borlaug, Kavita Sharma, Sanjiv J. Shah, Jennifer E. Ho
Summary: The incidence and prevalence of heart failure with preserved ejection fraction (HFpEF) is increasing due to aging, obesity, sedentariness, and cardiometabolic disorders. Despite recent advances in understanding its pathophysiological effects and introduction of new diagnosis approaches, HFpEF remains under-recognized. This is concerning as effective treatments have been identified. This article provides an in-depth examination of the epidemiology, pathophysiology, diagnosis, and treatment of HFpEF. (J Am Coll Cardiol 2023;81:1810-1834) (c) 2023 by the American College of Cardiology Foundation.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2023)
Letter
Medicine, General & Internal
Elric Zweck, Ralf Westenfeld, Bjorn Redfors, Elmir Omerovic, Robin A. P. Weir, Domenico Gabrielli, Fabrizio Oliva, Giuseppe Zuccala, Scott D. Solomon, Muthiah Vaduganathan, John J. V. McMurray
Summary: Solomon et al. report on the DELIVER trial, which showed that dapagliflozin reduced risks of heart failure-related outcomes in patients with a mildly reduced or preserved left ventricular ejection fraction. These findings are expected to influence guidelines and clinical practice. The trial also confirmed dapagliflozin's efficacy in patients with a left ventricular ejection fraction of 60% or above.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Cardiac & Cardiovascular Systems
Hidemi Sorimachi, Kazunori Omote, Massar Omar, Dejana Popovic, Frederik H. Verbrugge, Yogesh N. Reddy, Grace Lin, Masaru Obokata, John M. Miles, Michael D. Jensen, Barry A. Borlaug
Summary: Central obesity is more common than general obesity in HFpEF, and there are significant sex differences in its relationships with metabolic abnormalities and hemodynamic perturbations, with greater impact in women.
EUROPEAN JOURNAL OF HEART FAILURE
(2022)
Article
Medicine, General & Internal
Stefan D. Anker, Javed Butler, Gerasimos Filippatos, Joao P. Ferreira, Edimar Bocchi, Michael Boehm, Hans-Peter Brunner-La Rocca, Dong-Ju Choi, Vijay Chopra, Eduardo Chuquiure-Valenzuela, Nadia Giannetti, Juan Esteban Gomez-Mesa, Stefan Janssens, James L. Januzzi, Jose R. Gonzalez-Juanatey, Bela Merkely, Stephen J. Nicholls, Sergio V. Perrone, Ileana L. Pina, Piotr Ponikowski, Michele Senni, David Sim, Jindrich Spinar, Iain Squire, Stefano Taddei, Hiroyuki Tsutsui, Subodh Verma, Dragos Vinereanu, Jian Zhang, Peter Carson, Carolyn Su Ping Lam, Nikolaus Marx, Cordula Zeller, Naveed Sattar, Waheed Jamal, Sven Schnaidt, Janet M. Schnee, Martina Brueckmann, Stuart J. Pocock, Faiez Zannad, Milton Packer
Summary: Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Cardiac & Cardiovascular Systems
Chanchal Chandramouli, Tay Wan Ting, Jasper Tromp, Anubha Agarwal, Sara Svedlund, Antti Saraste, Camilla Hage, Ru-San Tan, Lauren Beussink-Nelson, Maria Lagerstrom Fermer, Li-Ming Gan, Lars Lund, Sanjiv J. Shah, Carolyn S. P. Lam
Summary: Sex differences in coronary microvascular dysfunction (CMD) in heart failure with preserved ejection fraction (HFpEF) were investigated. The proteomic profiles associated with CMD differed between men and women with HFpEF. In men, CMD was associated with inflammation-mediated chemokine and cytokine signalling pathway, while in women, CMD was associated with pathways related to diabetes and other protein-related signalling.
EUROPEAN JOURNAL OF HEART FAILURE
(2022)
Letter
Medicine, General & Internal
Debdatta Bhattacharyya, Ayan Kar, Saurabh Dhumale, Filippos K. Triposkiadis, Andrew Xanthopoulos, Efstathios K. Iliodromitis, James Amato, Hiddo J. L. Heerspink, Lesley Inker, Tom Greene, Stefan D. Anker, Javed Butler, Milton Packer
Summary: In patients with heart failure and preserved ejection fraction, Empagliflozin reduced the incidence of primary outcome events compared to other drugs, but had higher rates of cardiovascular death, death from any cause, and hospitalization for heart failure compared to spironolactone.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Cardiac & Cardiovascular Systems
Rebecca Crosier, Amelie Paquin, Tina Zhu, Rob S. Beanlands, Lisa Mielniczuk, Robert A. de Kemp, Thais Coutinho
Summary: HFpEF predominantly affects females and is associated with systemic and coronary arterial abnormalities. A study on 32 participants with HFpEF and 26 controls found that female HFpEF patients had higher arterial load and impaired coronary microvascular function compared to males with HFpEF and control females. In contrast, there were no significant differences in arterial hemodynamics between control males and females.
AMERICAN JOURNAL OF CARDIOLOGY
(2023)
Review
Medicine, General & Internal
Margaret M. Redfield, Barry A. Borlaug
Summary: HFpEF affects approximately 3 million people in the US and up to 32 million people worldwide, and risk factors include older age, hypertension, diabetes, dyslipidemia, and obesity. First-line therapy for HFpEF includes sodium-glucose cotransporter type 2 inhibitors, exercise, HF self-care, loop diuretics as needed, and weight loss for patients with obesity and HFpEF.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2023)
Article
Cardiac & Cardiovascular Systems
Sebastian Rosch, Karl-Patrik Kresoja, Christian Besler, Karl Fengler, Anne Rebecca Schoeber, Maximilian von Roeder, Christian Luecke, Matthias Gutberlet, Karin Klingel, Holger Thiele, Karl-Philipp Rommel, Philipp Lurz
Summary: In this study, patients with heart failure with preserved ejection fraction (HFpEF) were stratified based on left ventricular ejection fraction (LVEF), resulting in distinct morphologic and pathophysiologic subphenotypes. Patients with LVEF ranging from 50% to 60% demonstrated reduced contractility, impaired ventriculo-arterial coupling, and higher extracellular volume fraction, while patients with LVEF >60% exhibited a hypercontractile state with excessive left ventricular afterload and diminished preload reserve.
Article
Geriatrics & Gerontology
Melissa C. Caughey, Muthiah Vaduganathan, Sameer Arora, Arman Qamar, Robert J. Mentz, Patricia P. Chang, Clyde W. Yancy, Stuart D. Russell, Sanjiv J. Shah, Wayne D. Rosamond, Ambarish Pandey
Summary: Obesity is more prevalent in black patients compared to white patients in a decade-long community surveillance of older hospitalized patients with HFpEF, but the gap has narrowed in recent years due to increasing obesity rates among white patients. Both races had the worst survival outcomes with class III obesity. Effective strategies are needed to manage obesity in patients with HFpEF.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
(2021)
Article
Cardiac & Cardiovascular Systems
Jiaxing Sun, Shi Tai, Yanan Guo, Liang Tang, Hui Yang, Xuping Li, Zhenhua Xing, Liyao Fu, Shenghua Zhou
Summary: Among elderly patients with HFpEF, women had worse cardiac function but better survival and lower HF-related hospitalization rate than men.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2021)
Article
Cardiac & Cardiovascular Systems
Jasper Tromp, Brian L. Claggett, Jiankang Liu, Alice M. Jackson, Pardeep S. Jhund, Lars Kober, Jiri Widimsky, Sergey A. Boytsov, Vijay K. Chopra, Inder S. Anand, Junbo Ge, Chen-Huan Chen, Aldo P. Maggioni, Felipe Martinez, Milton Packer, Marc A. Pfeffer, Burkert Pieske, Margaret M. Redfield, Jean L. Rouleau, Dirk J. Van Veldhuisen, Faiez Zannad, Michael R. Zile, Adel R. Rizkala, Akiko Inubushi-Molessa, Martin P. Lefkowitz, Victor C. Shi, John J. McMurray, Scott D. Solomon, Carolyn S. P. Lam
Summary: In the PARAGON-HF trial, regional differences in clinical characteristics and outcomes were observed among patients with HFpEF, which may have implications for the design of future clinical trials.
CIRCULATION-HEART FAILURE
(2021)